证券代码：688319 证券简称：欧林生物 公告编号：2025-049 成都欧林生物科技股份有限公司关于持股 5%以上股 东权益变动触及 1%刻度的提示性公告 上海武山生物技术有限公司及其一致行动人樊绍文、樊钒保证向本公司提供的信 息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 3.一致行动人信息 关系说明：上海武山生物技术有限公司(以下简称"上海武山")为樊绍文、 樊钒控制的企业。樊绍文、樊钒为父女关系。 二、 权益变动触及 1%刻度的基本情况 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | √控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | - ...

成都欧林生物科技股份有限公司发布公告，其控股股东上海武山生物技术有限公司及其一致行动人樊绍 文、樊钒权益变动触及1%刻度。2025年9月4日 - 29日，上海武山通过集中竞价和大宗交易方式减持股 份，目前减持计划尚未实施完毕。变动后，三者合计持股比例从29.00%降至27.92%，其中仅上海武山 直接持股变动。本次减持是履行此前披露计划，不触及要约收购，不会使控股股东及实控人变化，也不 影响公司治理与经营。信息披露义务人将依规减持并及时披露进展。 ...

Core Viewpoint - On September 29, 2023, Olin Bio reported significant trading activity on the block trading platform, with a total transaction volume of 1.2019 million shares and a total transaction value of 25.584 million yuan, indicating a trend of discounted trading relative to the closing price [2] Trading Activity Summary - The three block trades on September 29 had transaction prices that were at a discount to the closing price, with the highest discount reaching 23.16% [2] - Over the past three months, Olin Bio has recorded a total of 11 block trades, amounting to 55.3507 million yuan [2] Stock Performance Summary - Olin Bio's closing price on September 29 was 26.68 yuan, reflecting an increase of 4.63% for the day, with a turnover rate of 1.62% and a total trading volume of 174 million yuan [2] - The stock experienced a net outflow of 4.2742 million yuan in main funds for the day, and over the past five days, the stock has declined by 2.56% with a total net inflow of 1.1935 million yuan [2] Margin Trading Data - The latest margin financing balance for Olin Bio is 311 million yuan, which has decreased by 19.3307 million yuan over the past five days, representing a decline of 5.85% [2] Company Background - Chengdu Olin Bio Technology Co., Ltd. was established on December 11, 2009, with a registered capital of 405.9336 million yuan [2]

9月29日，欧林生物大宗交易成交120.19万股，成交额2558.4万元，占当日总成交额的12.83%，成交均 价21.29元，较市场收盘价26.68元折价20.22%，其中最高成交价22.6元，最低成交价20.5元。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) | | 成交金额(万元) 成交量(*) 买入营业部 | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-29 | 欧林生物 | 688319 | 22.6 | 1017 | 45 | 2017 11:52 | 全面度最高出货器 | 140 | | 2025-09-29 | 欧林生物 | 612899 | 20.5 | 881.5 | 43 | 容自身有人民常落 | 不會議是大賞為醫 | KI | | 2025-09-29 | 欧林生物 | 688319 | 20.5 | 659.9 | 32.19 | 茶量度發展開發 | 不動量發送與點點 | Ka | ...

Group 1 - The core point of the article highlights the recent performance of Olin Biological, which saw a 5.1% increase in stock price, reaching 26.80 yuan per share, with a total market capitalization of 10.879 billion yuan [1] - Olin Biological, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine at 90.99% [1] - The company also generates revenue from other vaccines, including A group C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae type b conjugate vaccine (3.99%), and others [1] Group 2 - From the perspective of fund holdings, Olin Biological is a significant investment for the Fuyong Fund, with its Fuyong Medical Health Mixed Fund A (015655) holding 17,200 shares, representing 2.06% of the fund's net value [2] - The fund has seen a floating profit of approximately 22,400 yuan from this investment, with a total fund size of 11.8186 million yuan [2] - Year-to-date, the fund has achieved a return of 14.22%, with a one-year return of 10.55%, although it has experienced a loss of 20.8% since its inception [2]

Summary of Key Points Core Viewpoint - A significant block trade of 160,000 shares of Olin Bio occurred on September 24, with a transaction value of 3.5856 million yuan, reflecting a discount of 16.32% compared to the closing price of the day [2][3]. Trading Activity - In the last three months, Olin Bio has recorded a total of 8 block trades, with a cumulative transaction value of 29.7667 million yuan [3]. - The closing price of Olin Bio on the day of the block trade was 26.78 yuan, which represents an increase of 1.59% for that day [3]. - The daily turnover rate for Olin Bio was 1.21%, with a total trading volume of 130 million yuan, and a net outflow of main funds amounting to 3.5702 million yuan [3]. Financing and Capital Structure - The latest margin financing balance for Olin Bio stands at 316 million yuan, showing a decrease of 6.9697 million yuan over the past five days, which is a decline of 2.16% [4]. - Olin Bio was established on December 11, 2009, with a registered capital of 405.9336 million yuan [4].

Core Viewpoint - Oulin Bio is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure, following the termination of its previous fundraising plan [1][2][3]. Group 1: H-Share Listing Plans - Oulin Bio is currently in discussions with relevant intermediaries regarding the H-share listing, with specific details yet to be determined [1][2]. - The H-share listing will require approval from the company's board, shareholders, and various regulatory bodies, including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]. Group 2: Termination of Previous Fundraising - The company recently terminated a year-long plan for a private placement that aimed to raise 1.25 billion yuan for the renovation of its vaccine R&D production base [3]. - The initial private placement plan was announced in June of the previous year, with a target of 1.75 billion yuan, but was later reduced due to market conditions [3]. Group 3: Financial Performance - In the first half of the year, Oulin Bio achieved a revenue of 306 million yuan, a year-on-year increase of 35.17%, and a net profit of 13.2 million yuan, marking a return to profitability [4]. - The company's core product, the Tetanus Toxoid Vaccine, has shown significant revenue growth, contributing to 90.99% of total revenue in the first half of the year [4]. Group 4: R&D and Future Projects - Oulin Bio is focusing on balancing R&D investment with operational cash flow, with a total R&D expenditure of 65.25 million yuan in the first half of the year, accounting for 21.33% of revenue [5]. - The company is advancing its pipeline projects, including the recombinant Staphylococcus aureus vaccine, which is expected to complete its Phase III clinical trials by mid-2026 [4][5].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase its global visibility, and optimize its capital structure [1][2]. Group 1 - The company is currently discussing the details of the H-share listing with relevant intermediaries, and specific details have not yet been finalized [2]. - The H-share listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, the Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]. - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations as the H-share listing progresses [2].

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

★ 宏观动态 ★ 经合组织预测2025年全球经济增速为3.2%，2026年将放缓至2.9% 经济合作与发展组织（经合组织）23日发布中期经济展望报告，预计2025年全球经济增速为3.2%，较今年6月 预测值上调0.3个百分点；2026年全球经济增速将放缓至2.9%，与6月预测值相同。 陕西省省长赵刚：中欧班列西安集结中心已开通国际干线18条、覆盖亚欧大陆全境 陕西省省长赵刚今日在2025欧亚经济论坛上表示，中欧班列西安集结中心已开通国际干线18条、覆盖亚欧大陆 全境，核心指标稳居全国第一，上半年开行3055列、同比增长28.8%。西安国际航空枢纽，已开通国际客运航 线60条、全货运航线16条，上半年国际航班客运量、货运量分别增长71%和124.8%。我们持续提升枢纽的承载 力、辐射力，推动港产港贸港城融合发展，引导外向度高的适铁、临空产业集聚发展。如今，中欧班列满载着 汽车、光伏、家电等"陕西制造"横贯欧亚、走向世界。 工信部：组合驾驶辅助系统乘用车新车市场渗透率超60% 香港交易所今天宣布与广州碳排放权交易中心有限公司，深圳绿色交易所， 澳门国际碳排放权交易所签署合 作备忘录，携手推动粤港澳大湾区碳市场及绿 ...